Fresenius

Fresenius, a medical and precision instruments company headquartered in Germany, has outlined significant carbon emission reduction goals. For the reporting year 2025, the company reported a total of approximately 4.26 billion kg CO2e. Of this, Scope 1 emissions were about 317.4 million kg CO2e, Scope 2 emissions were around 170.5 million kg CO2e, and Scope 3 emissions accounted for the largest portion at approximately 3.77 billion kg CO2e.

Looking at prior years, Fresenius reported total emissions of about 4.29 billion kg CO2e in 2024, with Scope 1 at approximately 351.1 million kg CO2e, Scope 2 at about 187.3 million kg CO2e, and Scope 3 at around 3.75 billion kg CO2e. In 2023, total emissions were approximately 4.24 billion kg CO2e, comprising about 344.2 million kg CO2e for Scope 1 and approximately 235 million kg CO2e for Scope 2. Scope 3 data for 2023 indicates about 3.66 billion kg CO2e, with a notable omission in the "purchased goods and services" category.

Fresenius is committed to achieving climate neutrality by 2040. A key near-term target is to reduce absolute Scope 1 and Scope 2 emissions by 50% by 2030, using 2020 as the baseline year. Fresenius Medical Care, a part of the group, specifically aims to reduce its Scope 1 emissions by 30% from a 2020 baseline by 2030 and is planning to reduce its Scope 1 and 2 emissions to near zero by mid-decade. The company also has a long-term goal of achieving net zero across its entire value chain (Scopes 1 to 3) by 2050.